A transgenic mouse expressing human CYP4B1 in the liver.

The human CYP4B1 protein was expressed in the liver of a transgenic mouse line under the control of the promoter of the human apolipoprotein E (apo E) gene. Hepatic microsomes of transgenic mice catalyzed omega-hydroxylation of lauric acid and also activated 2-aminofluorene (2-AF), which is a typical substrate for CYP4B1, to mutagenic compounds detected by an umu gene expression assay. These activities observed in transgenic mouse were efficiently inhibited by CYP4B1 antibody. However, such inhibition was not observed in control mice. This is the first report to indicate catalytic activities of human CYP4B1. For further characterization of human CYP4B1, a fusion protein of CYP4B1 and NADPH-P450 reductase was expressed in yeast cells. It was able to activate 2-AF and was also able to catalyze omega-hydroxylation of lauric acid. This transgenic mouse line and the recombinant fusion protein provide a useful tool to study human CYP4B1 and its relation to chemical toxicity and carcinogenesis.

[1]  S. Imaoka,et al.  CYP4B1 is a possible risk factor for bladder cancer in humans. , 2000, Biochemical and biophysical research communications.

[2]  A. Bonazzi,et al.  Regulation of Cyclooxygenase-2 by Hypoxia and Peroxisome Proliferators in the Corneal Epithelium* , 2000, The Journal of Biological Chemistry.

[3]  E. Oliw,et al.  Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles. , 1999, Biochemical and biophysical research communications.

[4]  C. Wolf,et al.  Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo. , 1999, Archives of biochemistry and biophysics.

[5]  M. Schwartzman,et al.  Hypoxia-induced production of 12-hydroxyeicosanoids in the corneal epithelium: involvement of a cytochrome P-4504B1 isoform. , 1999, The Journal of pharmacology and experimental therapeutics.

[6]  Y. Fujii‐Kuriyama,et al.  Identification of a meander region proline residue critical for heme binding to cytochrome P450: implications for the catalytic function of human CYP4B1. , 1998, Biochemistry.

[7]  F. Gonzalez,et al.  Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. , 1998, Pharmacogenetics.

[8]  S. Imaoka,et al.  Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. , 1997, Archives of biochemistry and biophysics.

[9]  S. Fukushima,et al.  Mutagenic activation of urinary bladder carcinogens by CYP4B1 and the presence of CYP4B1 in bladder mucosa. , 1997, Biochemical pharmacology.

[10]  M. Katsuki,et al.  Establishment of transgenic mice carrying human fetus-specific CYP3A7. , 1996, Archives of biochemistry and biophysics.

[11]  T Sakaki,et al.  Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. , 1996, Biochemical pharmacology.

[12]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[13]  J. Taylor,et al.  Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Yamazaki,et al.  Mutagenic activation of 3-methoxy-4-aminoazobenzene by mouse renal cytochrome P450 CYP4B1: cloning and characterization of mouse CYP4B1. , 1995, Archives of biochemistry and biophysics.

[15]  D. Dinsdale,et al.  CYP4B1 activates 4-ipomeanol in rat lung. , 1993, Toxicology and applied pharmacology.

[16]  K. Korzekwa,et al.  Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. , 1991, Cancer research.

[17]  H. Murakami,et al.  Expression of bovine cytochrome P450c21 and its fused enzymes with yeast NADPH-cytochrome P450 reductase in Saccharomyces cerevisiae. , 1990, DNA and cell biology.

[18]  S. Imaoka,et al.  Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation. , 1990, Archives of biochemistry and biophysics.

[19]  S. Imaoka,et al.  Characterization of three cytochrome P450s purified from renal microsomes of untreated male rats and comparison with human renal cytochrome P450. , 1990, Archives of biochemistry and biophysics.

[20]  O. Mcbride,et al.  Identification of a new P450 expressed in human lung: complete cDNA sequence, cDNA-directed expression, and chromosome mapping. , 1989, Biochemistry.

[21]  R. Gasser,et al.  Primary structures of cytochrome P-450 isozyme 5 from rabbit and rat and regulation of species-dependent expression and induction in lung and liver: identification of cytochrome P-450 gene subfamily IVB. , 1989, Molecular pharmacology.

[22]  F. Guengerich.  Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. , 1988, Cancer research.

[23]  T. Eling,et al.  The cytochrome P-450 monooxygenase system of rabbit bladder mucosa: enzyme components and isozyme 5-dependent metabolism of 2-aminofluorene. , 1985, Cancer research.

[24]  C. Wolf,et al.  The rabbit pulmonary monooxygenase system. partial structural characterization of the cytochrome P-450 components and comparison to the hepatic cytochrome P-450. , 1981, The Journal of biological chemistry.

[25]  J. Radomski,et al.  - Hydroxylase Activity N 4-Aminobiphenyl Bovine Bladder Mucosa Microsomal Cytochrome P-450 and Updated Version , 2006 .

[26]  Y. Yabusaki.  Artificial P450/reductase fusion enzymes: what can we learn from their structures? , 1995, Biochimie.